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Abstract
Key regulators of the Wnt signalling, DVL1, DVL2 and DVL3, in astrocytomas of
different malignancy grades were investigated. Markers for DVL1, DVL2 and DVL3
were used to detect microsatellite instability (MSI) and gross deletions (LOH), while
immunohistochemistry and immunoreactivity score were used to determine the sig-
nal strengths of the three DVL proteins and transcription factors of the pathway,
TCF1 and LEF1. Our findings demonstrated that MSI at all three DVL loci was con-
stantly found across tumour grades with the highest number in grade II (P = 0.008).
Collectively, LOHs were more frequent in high‐grade tumours than in low grade
ones. LOHs of DVL3 gene were significantly associated with grade IV tumours
(P = 0.007). The results on protein expressions indicated that high‐grade tumours
expressed less DVL1 protein as compared with low grade ones. A significant nega-
tive correlation was established between DVL1 expression and malignancy grades
(P < 0.001). The expression of DVL2 protein was found similar across grades, while
DVL3 expression significantly increased with malignancy grades (P < 0.001). The
signal strengths of expressed DVL1 and DVL3 were negatively correlated
(P = 0.002). However, TCF1 and LEF1 were both significantly upregulated and
increasing with astrocytoma grades (P = 0.001). A positive correlation was estab-
lished between DVL3 and both TCF1 (P = 0.020) and LEF1 (P = 0.006) suggesting
their joint involvement in malignant progression. Our findings suggest that DVL1
and DVL2 may be involved during early stages of the disease, while DVL3 may
have a role in later phases and together with TCF1 and LEF1 promotes the activa-
tion of Wnt signalling.
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1 | INTRODUCTION
Astrocytomas are the most common and deadliest form of primary
brain tumours.1 According to the World Health Organization (WHO)
classification, there are four grades of astrocytic brain tumours, con-
sidering their histology, molecular characteristics and prognosis.2 The
least aggressive are pilocytic astrocytomas corresponding to WHO
grade I, while diffuse (grade II) and anaplastic astrocytomas (grade III)
are malignant types with intrinsic ability to progress to higher grades
of malignancy. Of these, glioblastoma multiforme (grade IV) is the
most aggressive, fastest‐growing and highly invasive tumour with
survival times of about a year.3 Despite recent advances in under-
standing the molecular basis of astrocytoma development and pro-
gression, additional research is required to develop more effective
therapies.
By its biological characteristics astrocytomas are genetically and
pathohistologically a very heterogeneous group of tumours. Com-
plex mechanism of gliomagenesis is the outcome of overlapping
between altered signalling pathways. A long‐scale study conducted
by The Cancer Genome Atlas (TCGA) revealed numerous data on
specific genetic and epigenetic alterations underlying gliomas.4
Although it is still not possible to define the exact number and
chronology of changes during gliomagenesis, they found that key
genes responsible for the formation and progression of astrocytic
brain tumours are most frequently involved into deregulated onco-
genic pathways: RTK/RAS/PI3K, TP53 and RB.4,5 Recent studies
have shown that altered signal transduction in Wnt signalling path-
way is also involved in the molecular pathogenesis of glial
tumours.6-9
The Wnt signalling is an evolutionarily conserved pathway that
plays very important roles during embryonic development and
tumourigenesis.10 In the absence of Wnt ligand, cytoplasmic
β‐catenin protein is constantly being degraded by the action of the
destruction complex composed of Axin, APC and 2 phosphokinases:
casein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3). CK1
and GSK3 phosphorylate β‐catenin, which leads to its proteasomal
degradation. Continuous elimination of β‐catenin from the cell pre-
vents β‐catenin from reaching the nucleus, thereby repressing tran-
scription of Wnt target genes.11,12
Binding of Wnt ligand to a Frizzled (Fz) receptor and its co‐
receptor LRP5/6 activates Wnt/β‐catenin pathway. In this stage the
concentration of DVL protein in cytoplasm increases, resulting in
recruitment of components of destruction complex to the cell mem-
brane. These events lead to inhibition of β‐catenin phosphorylation,
its stabilization and accumulation in the cytoplasm. β‐catenin trans-
fers to the nucleus where it forms complexes with T cell factor 1
(TCF1) and lymphoid‐enhancer factor 1 (LEF1) and in such a fashion
activates Wnt target gene transcription.13 DVL is the central compo-
nent of Wnt signalling and key cytoplasmic regulator that rescues β‐
catenin from degradation. Three homologous Dishevelled genes
(DVL1, DVL2 and DVL3), that show a high degree of similarity, have
been found in humans. Knock-out mouse models have shown that
each of the DVL proteins can act individually but also in the
combination with other family members.14 Dishevelled gene proteins
function as branching points for the differential interpretation of dis-
tinct Wnt ligands.15 They are activated by phosphorylation in
response to Wnt signals; whereas the ubiquitination of DVL proteins
leads to an effective inhibition of the β‐catenin destruction com-
plex.13 It has been postulated that DVL overexpression may play a
role in the progression of several cancers.16-20 As a result it repre-
sents a potential target for cancer therapy.
In the present investigation, we searched for changes of all three
human DVL genes and proteins and tried to define their involvement
in specific astrocytoma grade. We were also interested about their
effect on Wnt signalling activation and examined transcription fac-
tors TCF1 and LEF1.
2 | METHODS
2.1 | Tumour specimens
Eighty‐three astrocytoma samples together with corresponding
autologous blood tissue were collected with patients’ consents
from the Departments of Neurosurgery and Departments of Pathol-
ogy University Hospital Centers “Zagreb” and “Sisters of Charity”,
Croatia and Brain Tumour Tissue Banks from Croatia and Canada.
All tumours were studied by certified neuropathologist and classi-
fied according to the WHO criteria.2 The patients had no family
history of brain tumours and did not undergo any cancer treatment
(chemotherapy or radiotherapy) prior to surgery. The sample con-
sisted of 17 pilocytic astrocytomas (grade I), 14 diffuse (grade II),
17 anaplastic (grade III) and 35 glioblastomas (grade IV). Thirty‐six
patients were female and 47 male. The age of patients varied from
2 to 77 (mean age = 45, median = 44 years). The mean age of diag-
nosis for females was 49 (median 54.5) and for males 42 years
(median 41).
Ethical approval was received from the Ethics Committees
School of Medicine University of Zagreb (Case number: 380‐59‐
10106‐14‐55/147; Class: 641‐01/14‐02/01) and University Hospital
Centers “Sisters of Mercy” (number EP‐7426/14‐9) and “Zagreb”
(number 02/21/JG, class: 8.1.‐14/54‐2). Patients gave their informed
consent.
2.2 | DNA extraction
For the genomic DNA extraction, approximately 0.5 g of tumour tis-
sue was homogenized with 1 mL extraction buffer (10 mmol L−1
Tris–HCl, pH 8.0; 0.1 M EDTA, pH 8.0; 0.5% sodium dodecyl sulfate)
and incubated with proteinase K (100 μg/mL; Sigma‐Aldrich, St.
Louis, MO, USA) overnight at 37°C. Phenol chloroform extraction
and ethanol precipitation followed. Blood was used to extract DNA
from leukocyte. Five millilitre of blood was lysed with 15 mL RCLB
(Red Blood Cell Lysis Buffer) (0.16 M NH4Cl; 10 mmol L
−1 KHCO3;
10 mmol L−1 EDTA; pH 7.6) and centrifuged (15 min/5000 g). After
overnight incubation with 2 mL SE buffer (Sodium‐EDTA; 75 mmol
L−1 NaCl; 25 mmol L−1 Na2EDTA; pH 8), 200 μL 10% SDS (Sodium‐
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dodecyl sulphate) and 15 μL proteinase K (Sigma, Germany) (20 mg/
mL) at 37°C, salting‐out method by isopropanol precipitation
followed.
2.3 | Polymerase chain reaction, multiplex PCR,
microsatellite instability, loss of heterozygosity
Genetic changes were tested using PCR amplification of polymorphic
microsatellite markers for DVL1 (D1S468 and D1S243), DVL2
(D17S960) and DVL3 (D3S1262) genes to detect microsatellite insta-
bility (MSI) and loss of heterozygosity (LOH).21 All markers were
amplified in a total volume of 25 μL: 5X PCR buffer, 1.5 mmol L−1
MgCl2, 2.5 mmol L
−1 of each dNTP, each primer 0.4 μmol, 100 ng
DNA, 1 U Taq polymerase (Promega, Fitchburg, WI, USA). PCR con-
ditions and primers for D1S468, D1S243, D17S960 and D3S1262
markers are shown in Table 1.
Marker D3S1262 was also used for multiplex PCR. It was amplified
in the same reaction together with markers for genes SHGC‐68373
(222 bp) 22 and Apex1 (321 bp) 23 that were used as references. Data
from the literature indicated that genetic regions where reference
genes are located are not changed in glioblastoma and therefore could
be used as reference to study oncogenic amplifications.
Genetic alterations were visualized on Spreadex EL 400 Mini gels
(Elchrom Scientific, ALLabortechnik, AL‐Diagnostic GmbH, Amstet-
ten, Austria) and stained with SYBR Gold (Invitrogen, Molecular
Probes, Eugene, OR, USA). Samples were considered positive for
MSI if additional DNA bands appeared in tumour sample, or if the
existing DNA bands have changed position in comparison to bands
of autologous blood tissue. Absence or significant decrease in the
intensity of one polymorphic allele in tumour as compared to the
DNA from autologous blood was considered as LOH.
2.4 | Microsatellite genotyping analysis
Loss of heterozygosity was confirmed by capillary electrophoresis
performed on instrument 3730XL (Applied Biosystems Inc.). The 5′‐
end of the forward primer was fluorescently labelled with a 6‐FAM
dye, and PCR amplification was performed with the AmpliTaq Gold
master‐mix (360) (Applied Biosystems Inc.). The labelled PCR prod-
ucts were separated using capillary electrophoresis. Alleles were
sized relative to an internal size standard (500 LIZ; Thermo Fisher
Scientific, Carlsbad, CA, USA). Raw data and graphical representation
of LOH samples were reviewed using GeneMapper 5 and Peak Scan-
ner (Thermo Fisher Scientific).
2.5 | Immunohistochemistry
In order to establish the levels of expression and cellular localization
of DVL1, DVL2, DVL3 gene products immunohistochemistry was
used, as well as for testing the upregulation of transcription factors,
TCF1 and LEF1. The samples were fixed in formalin, embedded in
paraffin, sliced into 4‐μm thick sections, and then fixed onto capillary
gap microscope slides (DakoCytomation, Glostrup, Denmark). Briefly,
sections were deparaffinized in xylene, rehydrated in decreasing con-
centrations of ethanol and then microwaved twice for 7 minutes at
400 W in citrate buffer and three times for 5 minutes at 700 W to
unmask epitopes. To block endogenous peroxidase activity, cells were
fixed in dark with 3% H2O2 for 10 minutes. Non‐specific binding was
blocked by incubating samples with protein block serum‐free ready‐
to‐use (Dako, Carpinteria, CA, USA) for 30 minutes at 4°C. Next, the
primary antibodies, mouse monoclonal anti‐human for DVL1, TCF1
and LEF1 (1:50; Santa Cruz Biotechnology Inc., Dallas, TX, USA) and
rabbit polyclonal anti‐human for DVL2 and DVL3 (1:500; 1:50,
Abcam, Cambridge, UK) were applied overnight at 4°C. Slides were
then washed three times in phosphate‐buffered saline (PBS), and sec-
ondary LINK antibody was applied for 30 min at 4°C. Slides were
again washed three times in PBS and incubated with substrate chro-
mogen solution (EnVision™, Dako REAL™) for 30 seconds. Sections
were immunostained using streptavidin horseradish peroxidase/DAB
(3,3‐diaminobenzidine) (Dako REAL™ EnVision™, Glostrup, Denmark).
The level of expression of DVL1, DVL2 and DVL3 proteins in
the healthy brain was determined by using cerebral cortex of human
brain (Amsbio, Oxfordshire, UK). We have found that the levels of
immunoreactivity of all homologues of the Dishevelled protein family
in the healthy brain tissue were very low, and the signal was present
only in the cytoplasm.
Negative controls underwent the same staining procedure but
without incubating samples with primary antibodies. The frontal cor-
tex of a healthy human brain, placenta, liver tissue and normal bron-
chial epithelia all served as positive controls. Antibody labelling was
analysed by three independent and blinded observers using an
Olympus BH‐2 microscope and a digital scanner (NanoZoomer
TABLE 1 PCR conditions for microsatellite markers D1S468, D1S243, D17S960 and D3S1262
Marker Initial denaturation Cycles Final extension Primers
D1S468 94°C 5 min 94°C 30 s 60°C 30 s 72°C 30 s 72°C 10 min 5′ TTAACCGTTTTGGTCCTACC 3′
5′ CTCTGACCAGCATTAAAGATTC 3′
D1S243 95°C 5 min 95°C 30 s 56°C 30 s 72°C 30 s 72°C 10 min 5′ CAC ACA GGC TCA CAT GCC 3′
5′ GCT CCA GCG TCA TGG ACT 3′
D17S960 95°C 5 min 95°C 30 s 58°C 30 s 72°C 30 s 72°C 30 s 5′ CAA TGG AAC CAA ATG TGG TC 3′
5′ AGT CCG ATA ATG CCA GGA TG 3′
D3S1262 94°C 5 min 94°C 30 s 56°C 35 s 72°C 30 s 72°C 10 min 5′ CGG CCC TAG GAT ATT TTC AA 3′
5′ CCA GTT TTT ATG GAC GGG GT 3′
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2.0‑RS; Hamamatsu Photonics, Hamamatsu, Japan). ImageJ software
(National Institutes of Health, Bethesda, MD, USA) was used to
determine the cell number and the intensity of protein expression.
We counted 200 cells in tumour hot spot area and performed semi‐
quantitative analysis introducing immunoreactivity score (IRS) in
order to determine the signal strength. Immunoreactivity score is a
factor that best correlates with computational photo analysis and
was calculated by multiplying the percentage of cells with a positive
signal in the sample (PP score) with staining intensity (SI score). PP
score was determined as follows: no immunopositivity in tumour
cells = score 0; 1%‐25% positive cells = score 1; >25%‐50% = score
2; >50%‐85% = score 3; >85% = score 4. SI score was assessed in
three categories mirroring staining intensities, no staining or weak =
score 1, moderate staining = score 2 and strong staining = score 3.
Immunoreactivity score in our study ranged from 0 to 12. For sta-
tistical analysis needs, IRS values were converted to numbers/sym-
bols: 1 (0/+) (IRS = 0‐4) no expression or very weak expression; 2
(++) (IRS = 6‐8) moderate expression; 3 (+++) (IRS = 9‐12) strong
expression.
2.6 | Statistical analysis
The statistical evaluations for all the obtained data including tumour
intracranial localization, pathohistological type and grade, age, sex,
genetic findings and protein expression findings were performed
with the SPSS v.19.0.1 (SPSS, Chicago, IL, USA) statistical program,
with the statistical significance set at P < 0.05.
The normality of the distribution of individual parameters within
a group was tested using a Kolmogorov‐Smirnov test for normality
where low significance (P < 0.05) indicates that the distribution sig-
nificantly differs from normal. Depending on the results of the analy-
sis and the number of patients per group, parametric and
nonparametric statistical tests were further used. The differences in
the frequency of the chosen parameters were analysed by Pearson's
χ2 test using Yates's correlation when appropriate. Differences in the
values between the four grades were tested by a one‐way variance
analysis (ANOVA) in the case of normal distribution. When the
assumptions of one‐way ANOVA are not met, Kruskal‐Wallis test
was applied. In the case of normal distribution, differences between
the two groups were tested by Student's t test, and in case of a
deviation from normality by the Mann‐Whitney test. When the dis-
tribution between individual parameters was normal, we used Pear-
son correlation, while values derived from Spearman correlation
were taken into account if distribution deviated from normality.
2.7 | Analysis of public databases cBioPortal,
COSMIC and GEPIA
In order to test the compatibility of our results we investigated data
from publicly available databases. Genetic changes publicly reported
on DVL genes were assessed from cBioPortal and COSMIC data-
bases,24,25 while survival plots were performed from GEPIA data-
base.26
3 | RESULTS
3.1 | MSI at all three DVL loci was constant across
tumour grades while LOHs were associated to higher
grades
Our study explored DVL1, DVL2 and DVL3 gene alterations in associ-
ation with tumour grade. The presence of LOH and MSI, two
aspects of the genomic instability of tumour cells, was detected in
astrocytoma of different malignancy grades.
For DVL1 gene analysis, two polymorphic microsatellite markers
located in the close proximity to DVL1 gene in chromosomal region
1p36 were selected. Marker D1S468 showed a substantial rate of
microsatellite instability (MSI) across all astrocytoma grades, pilocytic
(grade I) showed 21.4%, diffuse (grade II) 53.8%, anaplastic (grade III)
36.4% and glioblastoma (grade IV) 17.1%. Contrary LOH was
detected only in the highest grade—glioblastomas, in 8.6% of
patients (Table 2). Statistical analysis confirmed that the distribution
regarding tumour grades was significant. Genetic changes were sig-
nificantly more distributed to glioblastoma group (P = 0.020). Fur-
thermore, our results indicated that MSI was significantly associated
to diffuse astrocytomas (grade II) as compared with other astrocy-
toma grades (P = 0.008).
The second marker, D1S243, confirmed the constant rates of
MSI across all grades: grade I with 7.1%, grade II with 23.1%, grade
III with 18.2% and grade IV with 28.6% of MSI, whereas this marker
revealed LOH in grades III (18.2%) and IV (9.1%) tumours.
Collective results for both markers for DVL1 showed that MSI
was detected in 28.6% of pilocytic, 61.5% diffuse, 45.5% anaplastic
astrocytomas and in 34.3% of glioblastomas, while LOHs were found
in 18.2% of anaplastic and 17.2% of glioblastomas (Figure 1A).
For DVL2 gene analysis marker D17S960 was selected and it
showed a lower rate of MSI in all tumour grades, 7.1% in grade I,
15.4% in grade II, 0% in grade III and 8.6% in grade VI. Again grade
II tumours (diffuse) harboured the highest frequency of MSI. How-
ever, gross deletions of DVL2 were detected in all grades (Figure 1B).
Thus, grade II and III each harboured 33.3% of LOHs, followed by
grade IV with 21.7% and grade I with the lowest frequency of
12.5% (Table 2). The distribution of genetic changes was not signifi-
cantly associated to any specific grade (P = 0.843).
DVL3 gene was analysed with D3S1262 marker (Figure 1C).
Microsatellite instability rate was again relatively constant across
different grades (grade I with 21.4%; grade II with 15.4%; grade III
with 14.3% and grade IV with 14.3%) while gross deletions were
associated only to higher malignancy grades (grade III with 18.2%
and grade IV with 31.2%) (Table 2). Statistical analysis revealed
that LOH of DVL3 gene was significantly more frequent in
glioblastomas as compared with astrocytomas of lower grades
(P = 0.007).
To ascertain results on observed genetic changes, genotyping by
capillary electrophoresis was additionally performed and LOHs were
confirmed as shown in Figure 1D. Taking both approaches together
our findings were additionally confirmed.
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Besides gross deletions, DVL3 gene also showed amplifications in
8.6% of glioblastoma patients (Figure 1C). Polymorphic status of
used microsatellite markers and observed genetic changes of DVL1,
DVL2 and DVL3 genes are presented in Table 2.
3.2 | Low rate of somatic mutations and deletions
of DVL genes is reported on cBioPortal and COSMIC
databases
We tested public datasets downloaded from the Cancer Genome
Atlas Database, an open access database that is publicly available at
http://www.cbioportal.org and found that the numbers differed to
the results of our experiments. Combined collective public datasets
from eight studies that are examining low‐grade gliomas and
glioblastomas encompassing 4216 samples demonstrate the
TABLE 2 Polymorphic status of microsatellite markers used and
the observed genetic changes of DVL1, DVL2 and DVL3 genes
Patient no Grade
DVL1 DVL2 DVL3
D1S468 & D1S243 D17S960 D3S1262
1 I HETERO HOMO HETERO
2 I HETERO HOMO HETERO
3 I HETERO HETERO HETERO
4 I HETERO HETERO HETERO
5 I HETERO HETERO HOMO
6 I MSI LOH MSI
7 I HETERO HOMO MSI
8 I MSI MSI MSI
9 I HETERO HOMO HETERO
10 I MSI HOMO HETERO
11 I MSI HETERO HETERO
12 I HETERO HOMO HETERO
13 I HETERO HETERO HETERO
14 I HETERO HETERO HETERO
15 II HETERO HETERO HETERO
16 II HETERO LOH HETERO
17 II MSIa LOH MSI
18 II MSI HETERO HETERO
19 II MSI MSI HETERO
20 II MSIa HOMO HETERO
21 II HETERO HOMO HETERO
22 II HETERO HOMO HETERO
23 II MSI HETERO HETERO
24 II HETERO HETERO HOMO
25 II MSI MSI MSI
26 II MSI LOH HOMO
27 II MSI HETERO HETERO
28 III HETERO HOMO HETERO
29 III MSI HETERO LOH
30 III LOH LOH MSI
31 III MSI HOMO HETERO
32 III HETERO HETERO MSI
33 III HETERO HOMO HETERO
34 III MSI HOMO MSI
35 III MSI&LOH HETERO HETERO
36 III MSI HETERO HETERO
37 III MSI LOH HETERO
38 III HETERO HOMO HETERO
39 IV HETERO HOMO LOH
40 IV MSI&LOH HETERO HETERO
41 IV HETERO HETERO MSI
42 IV MSI HOMO HETERO
43 IV HETERO HOMO HETERO
44 IV MSI HOMO HOMO
(Continues)
TABLE 2 (Continued)
Patient no Grade
DVL1 DVL2 DVL3
D1S468 & D1S243 D17S960 D3S1262
45 IV LOH HETERO HETERO
46 IV MSI HETERO LOH
47 IV HETERO HOMO LOH
48 IV MSI HETERO HETERO
49 IV LOH LOH HETERO
50 IV HETERO HETERO HETERO
51 IV MSI HETERO LOH
52 IV HETERO HETERO LOH
53 IV HETERO HOMO MSI
54 IV HETERO HETERO HETERO
55 IV MSI MSI LOH
56 IV MSI HOMO LOH
57 IV MSI HOMO HETERO
58 IV MSI HETERO LOH
59 IV LOH&MSI HETERO HETERO
60 IV MSI MSI LOH
61 IV HETERO HETERO HOMO
62 IV HETERO HETERO MSI
63 IV LOH&MSI LOH HETERO
64 IV HETERO LOH HETERO
65 IV MSI HETERO HETERO
66 IV HETERO HETERO MSI
67 IV HETERO HOMO LOH
68 IV HETERO LOH HETERO
69 IV MSI MSI MSI
70 IV HETERO HOMO HETERO
71 IV LOH&MSI LOH HETERO
72 IV HETERO HETERO HETERO
73 IV HETERO HETERO HOMO
HETERO, heterozygous; HOMO, homozygous; MSI, microsatellite insta-
bility; LOH, loss of heterozygosity.
aMSI found by both markers.
KAFKA ET AL. | 645
following distribution: somatic mutations were found in 8/4216
(0.19%) cases for DVL1, 12/4216 (0.28%) for DVL2 and 5/4216
(0.12%) for DVL3. Amplifications are reported mainly for DVL3 (53
cases showed amplification). Nevertheless, low number of cases with
amplified DVL1 (0.19%) were also reported. Furthermore, deletions
of DVL1 were found in seven glioblastomas and deletions of DVL2 in
two glioblastomas, while deletions of DVL3 were not reported. A
low rate of fusion mutations was also reported. The reported muta-
tions are predominantly missense somatic mutations. It is also obvi-
ous that mutational burden is much more frequent in glioblastomas
than low‐grade tumours and those amplifications are particularly
associated to DVL3 gene and to glioblastomas. The publicly available
data for each DVL gene are shown in Figure 2.
3.3 | High grade tumours expressed less DVL1
protein as compared with low grade ones, the
expression of DVL2 protein was similar across grades,
while DVL3 expression increased with malignancy
grades
The effect of genetic changes on the protein expressions levels was
investigated in the same patients. The expression of DVL1 protein
greatly differed among different tumour grades. The highest number
of samples with moderate and strong signal was present in the
anaplastic astrocytoma group (92.9%) followed by pilocytic (85.7%)
and diffuse (70%), while glioblastomas showed low or lack of DVL1
expression in 67.6% of cases. Cell count analysis of DVL1 signal
F IGURE 1 Microsatellite instability (MSI), loss of heterozygosity (LOH) and amplification of A) DVL1, B) DVL2 and C) DVL3 gene in
astrocyoma samples on Spreadex gels. Lane M—100 bp DNA standard; odd lanes show astrocytoma samples; even lanes show corresponding
blood samples. Samples demonstrating MSI are indicated with blue arrow; samples demonstrating LOH are indicated with red arrow; samples
demonstrating amplification are indicated with green arrow. D) Confirmation of LOH samples by microsatellite genotyping analysis (capillary
electrophoresis). Upper figures show DNA samples isolated from the blood, while bottom figures show DNA samples isolated from tumour
tissue of the same patient
F IGURE 2 cBioPortal data sets querying 4238 samples in nine
studies for each DVL gene. Percentages of alteration frequencies of
the DVL genes are shown. A) DVL1; B) DVL2; C) DVL3
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strength showed statistically significant differences in the number of
cells with low, moderate and strong expression among different
tumour grades (P < 0.001). Glioblastomas had significantly more cells
with low expression as compared with pilocytic (P = 0.001) and
anaplastic astrocytomas (P = 0.001). Accordingly, glioblastomas had a
lower number of cells with strong DVL1 expression as compared
with pilocytic (P = 0.001) and anaplastic astrocytomas (P = 0.001).
Moreover, anaplastic astrocytomas showed significantly lower num-
ber of cells with low expression levels when compared with diffuse
astrocytomas (P = 0.008). Negative correlation between DVL1 pro-
tein expression and malignancy grades (rs = −0.479, df = 70,
P < 0.001) was established (Figure 3A). Of note, in tumours with
low levels of DVL1 expression, the signal was predominantly local-
ized in the cytoplasm or in the cytoplasm and cell membrane. In
tumours with moderate and strong expression levels of the DVL1
protein, the signal was significantly more frequently localized in cyto-
plasm and nucleus (P < 0.001).
The results of our study demonstrated increased DVL2 expres-
sion in all tumour grades when compared with the control tissue.
The highest number of samples with moderate and strong signal was
present in the group of anaplastic astrocytoma (77.6%) followed by
diffuse astrocytoma (70%), glioblastoma (61.7%) and pilocytic astro-
cytoma (57.2%). As the expression of DVL2 protein was closely the
same in all tumour grades, cell count analysis with respect to DVL2
signal strengths did not show significant differences among malig-
nancy grades (Figure 3B). Once again, tumours with the highest pro-
portion of cells with moderate and strong signal had protein located
in the cytoplasm and nuclei (P < 0.001).
Unlike the two previously analysed proteins, the DVL3 expres-
sion increase with malignancy grade was very pronounced. Glioblas-
toma had highest proportion of cells with moderate and strong
expression (82.4%) (Figure 3C), while astrocytomas grade I and II
were characterized with weak DVL3 expression, as none of the anal-
ysed samples showed more than 50% of positive cells in the tumour
hot spot area. Anaplastic astrocytomas had 7.2% samples with mod-
erate expression levels. Accordingly, cell count analysis regarding
DVL3 signal strength showed significant differences between tumour
grades (P < 0.001). Glioblastomas had the lowest number of cells
showing lack of expression and the highest number of cells showing
moderate and strong expression as compared to astrocytoma grades
I to III (P1 < 0.001; P2 = 0.001; P3 = 0.013, respectively). Tumours
with low signal intensities had predominant cytoplasmic localization,
while samples with moderate and strong expression had signal local-
ized in both the cytoplasm and the nucleus (P = 0.004) (Figure 3C).
This observation suggests that the increased DVL3 expression in
glioblastoma leads to more frequent transfer of this protein into the
nucleus (Figure 4).
3.4 | TCF1 and LEF1 protein expression levels
increased with astrocytoma grades
Next we asked how the Dishevelleds’ expression is impacting Wnt
signalling activation. For this we analysed the expression levels of
two transcriptional factors located at the end of the Wnt signalling
cascade, TCF1 and LEF1, whose elevated expression indicates the
activity of the pathway. Both factors were found to be expressed in
our total sample where the levels of both TCF1 and LEF1 expression
increased with astrocytoma grades. Accordingly, 61.1% of pilocytic
astrocytomas showed the lowest levels of TCF1 expression, while
weak or lack of TCF1 expression was confined to 50% of diffuse
astrocytomas. The highest expression levels were found in anaplastic
and glioblastomas cases, 77.8% and 80% respectively. The signal was
present exclusively in the nuclei of tumour cells (Figure 3D).
Statistical analysis for TCF1 protein showed that pilocytic had
significantly more cells with low expression levels as compared with
diffuse astrocytomas (P = 0.040) and glioblastomas (P = 0.003). Fur-
thermore, diffuse (P = 0.047), anaplastic (P = 0.022) astrocytomas
and glioblastomas (P = 0.001) had significantly higher number of cells
with strong TCF1 expression as compared with pilocytic (Figure 3D).
Similar results were obtained for LEF1 protein expression. Low
or lack of LEF1 expression was found in 61.1% of pilocytic astrocy-
tomas, while 70% of glioblastomas showed strong LEF1 expression.
Almost the same proportions of samples with moderate and strong
expression were present in the group of diffuse astrocytoma (88.9%)
and glioblastoma (90%), while in anaplastic cases the observed rate
was lower (66.6%).
The cell count analysis confirmed the previous observations.
Thus, pilocytic astrocytomas had significantly more cells with low
LEF1 expression than both diffuse astrocytomas (P = 0.006) and
glioblastomas (P = 0.001) (Figure 3E). The highest number of cells
with strong LEF1 expression was in glioblastomas comparing to pilo-
cytic (P < 0.001), diffuse (P = 0.032) and anaplastic types
(P = 0.003). Diffuse astrocytomas had significantly more cells with
strong LEF1 expression as compared with pilocytic (P < 0.001) and
anaplastic (P = 0.008), while anaplastic had significantly more cells
with strong LEF1 expression than pilocytic (P = 0.008) (Figure 3E).
The results on transcription factors suggest that Wnt activation is
accompanying the progression of the disease.
3.5 | The correlations of molecular findings and
clinical parameters
Immunoreactivity score values for DVL1, DVL2 and DVL3 were cal-
culated in order to determine the potential correlations between the
expression levels of the proteins.
There was no significant correlation between the expression
levels of DVL1 and DVL2 proteins (P = 0.799) (Figure 5A). However,
DVL1 and DVL3 were significantly negatively correlated in our total
sample (P = 0.002) (Figure 5B). Lower tumour grades (I and II)
showed significantly higher levels of DVL1 expression than high
grades (III and IV), while strong DVL3 expression was significantly
associated to high‐grade tumours. Comparing the IRS values for
DVL2 and DVL3, statistically significant negative correlation was
established only for pilocytic astrocytomas (r = −0.699, t = −3.388,
P = 0.005), while anaplastic astrocytomas showed a trend of nega-
tive correlation for the two proteins (r = −0.488, t = 0.236,
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F IGURE 3 Number of cells with (1) low, (2) moderate and (3) high levels of expression of A) DVL1, B) DVL2, C) DVL3, D) TCF1 and
E) LEF1 protein across different malignancy grades. Asterisks (*) denotes statistical significance (P < 0.05)
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P = 0.077) (Figure 5C). Correlation of IRS values for TCF1 and LEF1
revealed significant positive correlation between the two proteins
across all tumour grades (rs = 0.474, df = 92, P < 0.001) (Figure 5D).
Bivariate correlation of all analysed proteins revealed a statisti-
cally significant positive correlation between DVL3 and TCF1 (rs =
0.410, df = 30, P = 0.020) and DVL3 and LEF1 (rs = 0.475, df = 30,
P = 0.006). Correlation of DVL1 and TCF1; DVL1 and LEF1; DVL2
and TCF1; DVL2 and LEF1 showed no statistically significant associ-
ation between analysed proteins.
Finally we have found that two molecular parameters were signifi-
cantly associated with aging. Younger patients had a stronger DVL1
expression than older ones (rs = −0.226, df = 70, P = 0.057). On the
other hand, older patients had significantly higher DVL3 expression
comparing to the younger ones (rs = 0.395, df = 70, P = 0.001). No
statistical significance was found in relation to the sex of the patients.
Kaplan‐Meier survival curves were generated from GEPIA data-
base for each DVL member. The curves showed differences among
DVL genes expressions and overall and disease‐free survivals. The
plots are shown in Figure 6. The plots demonstrated that for low‐
grade astrocytomas (Figure 6B,D,F), the low expression levels of
DVL1 and DVL2 are correlated to better both overall and disease‐
free survival. The same applies for the disease‐free plot of DVL3,
while the overall survival plot shows similar survival for both low
and high DVL3 levels. Glioblastoma group (Figure 6A,C,E) shows dif-
ferences. Curves demonstrate similar survival for both high and low
DVL1 expression levels, however, disease‐free survival plots for
DVL2 and DVL3 show that higher levels of the proteins predict bet-
ter survival (Figure 6C,E).
4 | DISCUSSION
Despite advances in molecular and clinical oncology, in the case of
astrocytoma, and in particular glioblastoma, no significant progress
in the increase of the survival rates has been made over the last
decades. Therefore, the identification of novel molecular targets
responsible for tumour progression and biomarkers for prediction
of disease outcome and response to treatment is extremely requi-
site. Several novel studies indicate the involvement of Wnt signall-
ing in the molecular pathogenesis of glial tumours.7-9,20 However,
very little is known about the possible association of the proteins
involved in the Wnt pathway with tumour malignancy. Especially
rare are studies about the roles of DVL1, DVL2 and DVL3 in
human astrocytic brain tumours.27-29 The results of the present
study showed that genetic and protein changes of all three Dishev-
elleds have distinct roles in the process of astrocytoma formation
and progression.
We have found the constant rate of MSI across all astrocytoma
grades which indicates that genomic instability is part of genetic
blueprint of those tumours. Microsatellite instability at DVL1 locus
was detected in 28.6% of pilocytic, 61.5% diffuse, 45.5% anaplastic
astrocytomas and 34.3% of glioblastomas. Diffuse astrocytomas dis-
played significantly higher rate of DVL1 MSI than other astrocytoma
grades (P = 0.008). Although at a bit lower frequencies, MSI for
DVL2 was also constantly detected with the exception of anaplastic
astrocytomas. Nevertheless, diffuse type again showed the highest
number of MSI. For DVL3 gene MSI was constantly present across
different grades.
The lowest frequencies of DVL1 and DVL2 MSI were observed
for pilocytic astrocytomas which are benign tumours and not prone
to malignant progression. However, the highest MSI frequencies
were confined to diffuse cases suggesting that the increased geno-
mic instability could be characteristic for astrocytomas that are able
to progress to higher grades. It has been known that the increase of
mutation accumulation results in an acceleration of the tumour cell
evolution.30 But besides having effect on cell proliferation, the
increased rate of mutations within tumour cells could also lead to
cell death. Therefore, only those cells in which the number of muta-
tions does not exceed a certain threshold will have the potential to
proliferate. The lower frequencies of MSI found in glioblastomas for
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F IGURE 4 Characteristic immunohistochemical staining of DVL1, DVL2, DVL3, TCF1 and LEF1 proteins in astrocytoma. A) astrocytic brain
tumour grade I showing strong cytoplasmic and nuclear staining of DVL1, B) astrocytic brain tumour grade IV showing weak cytoplasmic
staining of DVL1, C) astrocytic brain tumour grade I showing strong nuclear staining of DVL2, D) astrocytic brain tumour grade IV showing
strong cytoplasmic staining of DVL2, E) astrocytic brain tumour grade I showing lack of expression of DVL3, F) astrocytic brain tumour grade
IV showing strong membranous, cytoplasmic and nuclear staining of DVL3, G) astrocytic brain tumour grade I showing weak nuclear
expression of TCF1, H) astrocytic brain tumour grade IV showing moderate and strong expression of TCF1, I) astrocytic brain tumour grade I
showing weak nuclear expression of LEF1, J) astrocytic brain tumour grade IV showing moderate and strong nuclear expression of LEF1. Scale
bar 50 μm
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all three DVL homologs could be explained by the inability of tumour
cells to proceed into much desired apoptosis.31
As MSI results from impaired DNA mismatch repair (MMR), sev-
eral groups32-36 analysed MMR genes in astrocytoma of different
grades but reported low rate of mutations. Nevertheless, the
observed presence of MSI may suggest that yet another mechanism
of MMR gene inactivation besides mutations is causative of this
molecular phenomenon in astrocytoma. Microsatellites are generally
found in non‐coding regions and their role in various malignant dis-
eases is still unexplained.37,38 Establishing a pattern of characteristic
microsatellite loci in tumours could have predictive potential for
tumour behaviour.
The results on gross deletions of the three human DVL genes
indicate that LOHs of DVL1 and DVL3 genes were confined only to
the high‐grade malignant group (grades III and IV) while LOHs of
DVL2 were appearing across all grades. Collectively for all DVL genes
the number of LOHs was much more frequent in higher‐grade
tumours (23 LOHs) than in low grade ones (4 LOHs). Statistical anal-
ysis pointed out that deletions of DVL3 gene were significantly asso-
ciated to the highest grade (P = 0.007) and could be connected to
tumour progression.
The chromosomal area on the chromosome 17 where DVL2 is
located was often deleted in our study. This is consistent with sev-
eral earlier studies investigating aberrations of chromosome 17 in
various tumour types including lung, breast, ovarian and brain
tumours.39-43 Lee et al39 found LOH on locus 17p in 50% of
anaplastic astrocytomas and glioblastomas, but did not detect it in
tumours of lower grades. We too, have found LOH to be more
F IGURE 5 Correlation between A) DVL1 and DVL2, B) DVL1 and DVL3, C) DVL2 and DVL3, D) TCF1 and LEF1 in astrocytic brain
tumours grades I‐IV
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frequent in malignant types (grades III and IV) or those types prone
to malignancy (grade II).
Genetic changes of DVL3 gene suggest its involvement in the
process of glioma progression. We noticed that the percentage of
LOH increased with the malignancy grade (grade III with 18.2% and
grade IV with 31.2%), while the presence of MSI was slightly
decreasing in higher grades (grade I with 21.4%; grade II with 15.4%;
grade III with 14.3% and grade IV with 14.3%). Statistical analysis
revealed that LOH of DVL3 was significantly more frequent in
glioblastomas than in lower‐grade tumours (P = 0.007). We also
found the amplification of DVL3 gene in 8.6% of glioblastoma which
could indicate different cellular roles for this gene. Other research
groups showed similar results. Hu et al44 detected 30% of glioblas-
tomas with LOH in the chromosomal region 3q where DVL3 is
located. On the other hand, Hui et al45 investigated amplifications in
the glioblastoma genome using the aCGH, and found that the region
3q was amplified in 14.3% of the tumour.
Data from cBioPortal and COSMIC databases24,25 report on low
rate of somatic mutations, fusions and deep deletions of all DVL
genes. However, the mutations that have been found are much more
frequent in glioblastomas than low‐grade tumours. The reported rate
of amplifications of DVL3 is similar to the ones we found.
Taken together, we showed that MSI occurred constantly across
all four tumour grades, with more frequent incidence in lower astro-
cytoma grades, suggesting its association with tumour formation.
Loss of heterozygosity was found to be often present in anaplastic
astrocytoma and glioblastoma and therefore could be involved in the
process of tumour progression as a background mechanism for inac-
tivation of tumour suppressor genes. All things considered, it is clear
that LOH and MSI contribute to the genomic profile of astrocy-
toma.46-49The levels of DVL1, DVL2 and DVL3 protein expressions
were studied as the functional consequences of each Dishevelled
homologue on astrocytoma tumour formation are still not fully clari-
fied, and the data from the literature are contradictory. Most studies
report on gene amplifications and high expression of DVL proteins
in general,17,50 but others describe large deletions of these genes as
well.51,52 Although our results generally showed higher DVL1
expression levels when compared to the control tissue, when
dividing the sample to malignancy grade groups it became obvious
that the expression levels of DVL1 differed significantly across
tumour grades (P < 0.001). Glioblastomas displayed predominant low
DVL1 expression, while anaplastic, pilocytic and diffuse astrocytomas
showed predominantly moderate and strong signals. Our results indi-
cate that expression levels of DVL1 dropped in the highest grade.
Glioblastomas had significantly more cells with low expression and
significantly less cells with strong expression as compared with pilo-
cytic (P < 0.001) and anaplastic astrocytomas (P < 0.001). Moreover,
diffuse astrocytomas had significantly more cells with low expression
when compared to anaplastic cases (P = 0.008). Negative correlation
between DVL1 protein expression and malignancy grades (rs =
−0.479, df = 70, P < 0.001) was established indicating that elevated
protein expression could be attributed to early events. Also younger
patients had a stronger DVL1 expression than older ones (rs =
−0.226, df = 70, P = 0.057). We also noticed that in tumours with
low DVL1 expression, the signal was predominantly localized in the
cytoplasm or in the cytoplasm and cell membrane, while in those
with moderate and strong expression, the signal was confined to
cytoplasm and nucleus (P < 0.001). Several authors showed that
DVL1 gene amplification and elevated protein expression are
involved in the development of breast and prostate cancer16,53,54
accompanied with positive correlation between DVL1 and β‐catenin
location in the nucleus.53
DVL2 was also upregulated in all tumour grades in comparison
to control samples. The highest number of samples with moderate
and strong signal was present in anaplastic astrocytoma (77.6%) fol-
lowed by diffuse astrocytoma (70%), glioblastoma (61.7%) and pilo-
cytic astrocytoma (57.2%). As the expression of DVL2 protein was
quite similar across tumour grades, cell count analysis of signal
strengths did not show significant differences among malignancy
grades. Once again, tumours with the highest proportion of cells
with moderate and strong signal had protein located in the cyto-
plasm and nuclei (P < 0.001). A study by Pulvirenti et al28 report on
increased DVL2 expression in 70% of glioblastomas. The authors
confirmed the role of DVL2 in human glioblastoma by DVL2 gene
attenuation using RNAi. Furthermore, when DVL2 activity was
decreased in the glioblastoma cells it prevented tumour development
F IGURE 6 Kaplan‐Meier survival curves generated from GEPIA database for each DVL member. A,B) represent DVL1; C,D) DVL2; E,F)
DVL3. A,C,E) demonstrate glioblastoma, B,D,F) low‐grade gliomas
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in the immunodeficiency mice. There are also studies showing that
DVL2 is involved in the progression of colon cancer.55
The clear picture on the increase of the expression levels with
the malignancy grade was obtained for DVL3. In all grade I and II
astrocytomas samples, DVL3 expression was characterized as weak,
while 82.4% of glioblastomas showed moderate and strong expres-
sion levels. Accordingly, cell count analysis regarding DVL3 signal
strength showed significant differences among tumour grades
(P < 0.001). Glioblastomas had the lowest number of cells showing
lack of expression and the highest number of cells showing moder-
ate and strong expression as compared to other grades (P1 < 0.001;
P2 = 0.001; P3 = 0.013 respectively). Unlike the two previously anal-
ysed proteins, the DVL3 expression increase with malignancy grade
was very pronounced. Of note is that older patients had significantly
higher DVL3 expression comparing to the younger ones (rs = 0.395,
df = 70, P = 0.001). There was no significant correlation between
the expression levels of DVL1 and DVL2 proteins (P = 0.799). How-
ever, DVL1 and DVL3 were significantly negatively correlated in our
total sample (P = 0.002). Stronger DVL1 expression was associated
to low‐grade tumours and strong DVL3 expression to high‐grade
tumours. As the correlation between the decreased protein expres-
sion of DVL3 and the presence of gross deletions has not been
established, there is a possibility that the observed LOHs are the
reflection of tumour heterogeneity occurring only in certain glioblas-
toma subtypes.
With regard to subcellular localization of DVL3 we noticed that
tumours with low signal intensities showed predominant cytoplasmic
localization, while moderate and strong expression was usually local-
ized in both the cytoplasm and the nucleus (P = 0.004). This obser-
vation suggests that the increased DVL3 expression in glioblastoma
leads to more frequent transfer of this protein into the nucleus. The
data from the literature report on two cellular pools of DVL: one in
the cytoplasm and another in the nucleus. Gan et al56 found that
DVL3 was accumulated in the nucleus in 36% of the analysed colon
cancer samples. It seems that DVL migrates from one cell compart-
ment to another after its concentration reaches a level necessary for
signal transduction. As our results of the bivariate correlation
between DVL3 and transcription factors TCF1 and LEF1 showed
that the proteins were significantly positively correlated, we can
assume that the increased DVL3 expression could ultimately lead to
enhanced transcriptional activity of target genes.
Similar to us, two studies17,27 also showed different behaviour of
DVL members in human tumours. Sareddy et al27 in astrocytoma
showed that the expression of DVL3 mRNA was elevated in all three
malignancy grades, while the expression of DVL1 and DVL2 mRNAs
was not detected. Authors also noticed a strong positive correlation
between DVL3, β‐catenin and LEF1 at the mRNA level, indicating
increased activity of the Wnt signalling pathway. Uematsu et al17
observed increased DVL3 expression in non‐small cell lung cancer,
while expression of DVL1 and DVL2 was not detected. Other papers
studied Dishevelled expression29,57 and found that it increased with
the histopathological grade. Dishevelled was positively correlated
with the proliferation index Ki‐67, tumour invasion index MMP‐9
and β‐catenin, and transferred to the nucleus which indicated its
involvement in the proliferation and invasion processes. Our group
previously analysed DVL1 and DVL3 proteins in metastases from
lung to the brain. The results showed elevated DVL1 (87.1%) and
DVL3 (90.3%) expression and cytoplasmic and nuclear localization of
the signal.58 It is important to discuss the potential roles that each
DVL member plays in signalling circumstances. Such studies are rare
and how DVLs conduct activity still remains poorly understood.
Firstly, it has been proposed that because of the high similarity of
DVL genes in mice and humans, members play equal roles and there
may be redundancy in how they work. However, Sharma et al,59
based on mouse knockout models, indicated that each DVL member
may have a unique role to play. To elucidate the specific roles of
DVL genes, rescue studies on double knockout mice were con-
ducted. Double knockout of DVL1 and DVL3 did not display neural
tube defects which indicate that each DVL has a unique role to play.
Another point in favour of different roles is the aberrant expression
of DVL genes linked to different human disorders. DVL1 has been
reported to be a candidate gene for human development disorder
Schwartz‐Jampel syndrome, Charcot‐Marie‐Tooth disease type 2A
and DiGeorge Syndrome, while DVL3 have been linked to Hirsch-
sprung's disease.
Interestingly, Sharma et al59 performed a TCGA analysis of
DVL1, DVL2 and DVL3 expression across of four different types of
cancer including glioblastoma and found that DVL RNA expression in
majority of those cancers did not differ as compared to adjacent nor-
mal tissues except for DVL1. The authors report on downregulation
of DVL1 RNA in glioblastoma and upregulation of DVL3 RNA in lung
cancer. This is very similar to our results and may suggest the impor-
tance of the post‐transcriptional regulation of DVL proteins. The
activation of Wnt signalling is primarily mediated by transcription
factors from the TCF/LEF family. It is well known that the TCF1 and
LEF1 proteins can have truly diverse effects in mediating signalling.
Their impact on activation or repression of the target genes depends
on the protein partner they interact with. Numerous studies investi-
gated TCF1 and LEF1 transcription factors in various tumour types
including colon, kidney, breast, adenocarcinoma, melanoma, several
different types of leukaemia and lymphoma59-61 and concluded that
their expression is important in maintaining the physiological func-
tions of cells, while their overexpression causes invasion of tumour
cells59 and promotes epithelial‐to‐mesenchymal transition.62
The results of our study showed that both TCF1 and LEF1
showed elevated expression and this upregulation indicates that the
Wnt pathway was activated. Moreover, the levels of both TCF1 and
LEF1 expression increased with astrocytoma grades. Astrocytomas
of higher grades had significantly higher number of cells with strong
TCF1 expression as compared with lower grades (P = 0.022 anaplas-
tic and P = 0.001 glioblastoma). Similarly, the highest number of cells
with strong LEF1 expression was confined to glioblastomas as com-
pared with pilocytic (P < 0.001), diffuse (P = 0.032) and anaplastic
types (P = 0.003). Correlation of IRS values for TCF1 and LEF1
revealed significant positive correlation between the two proteins
across all tumour grades (rs = 0.474, df = 92, P < 0.001).
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Positive correlation was established between DVL3 and both
TCF1 (rs = 0.410, df = 30, P = 0.020) and LEF1 (rs = 0.475, df = 30,
P = 0.006) indicating once again DVL3 link to progression.
There are several studies investigating the role of Wnt signalling
in human astrocytoma.27,63 Sareddy et al64 demonstrated strong
expression of TCF4 and LEF1 in diffuse, anaplastic astrocytomas and
glioblastomas. They showed that the activation of the transcription
factors was induced by β‐catenin migration into the nucleus. A posi-
tive correlation was also found between the expression level of
TCF4 and LEF1 compared to the astrocytoma grade. Although we
analysed another member of TCF family, the findings are still consis-
tent to our results.
Our previous study65 on beta‐catenin expression in neuroepithe-
lial brain tumours of different grades strengthens the claim on Wnt
signalling pathway's activity. We have shown that beta‐catenin was
upregulated in 53.1% of samples. Moreover, in 21.4% of glioblas-
tomas beta‐catenin was accumulated exclusively in the nucleus,
while in 38.1% in both the cytoplasm and nucleus.
5 | CONCLUSIONS
Together the results of this study show that important regulatory
components of the Wnt signalling pathway, DVLs, have different
roles in astrocytomas. Our study revealed that LOH and MSI con-
tribute to the genomic profile of astrocytoma. Furthermore, a
noticeable difference in the expression levels of DVL proteins in
different tumour grades was established. We have found that
DVL1 and DVL2 in astrocytic brain tumours act in one fashion and
may be involved during early stages of the disease, while DVL3
behaves differently being involved in the progression while having
activating effect on TCF1 and LEF1 transcription factors of Wnt
pathway.
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